The proposed research will determine the effectiveness of curcumin for improving the health and function of arteries in children and young adults with autosomal dominant polycystic kidney disease (ADPKD). The study also will provide insight into how curcumin improves artery health by determining the physiological mechanisms (biological reasons) involved and offer exploratory evidence if curcumin can slow kidney growth. This will be done by comparing these measurements in children and young adults who are randomized to receive either curcumin or placebo for 1 year.
Although often considered to be a disease of adults, complications of autosomal dominant polycystic kidney disease (ADPKD) begin in childhood. While ADPKD causes the continued growth of multiple kidney cysts that ultimately result in loss of kidney function, the leading cause of death among patients with ADPKD is cardiovascular disease. Treatment options to prevent cardiovascular disease in adults with ADPKD are limited, thus childhood may be an important time to reduce risk. Curcumin is a safe, naturally occurring substance found in the Indian spice tumeric, which is in curry powder. The proposed research will determine the effectiveness of curcumin for improving the health and function of arteries in children and young adults with ADPKD. The study also will provide insight into how curcumin improves artery health by determining the physiological mechanisms (biological reasons) involved and offer exploratory evidence if curcumin can slow kidney growth. This will be done by comparing these measurements in children and young adults who are randomized to receive either curcumin or placebo for 1 year.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
68
University of Colorado Anschutz Medical Campus
Aurora, Colorado, United States
Percent Change in Brachial Artery Flow-mediated Dilation (FMD-BA)
co-primary endpoint
Time frame: Baseline, Month 12
Change in Aortic Pulse-wave Velocity (aPWV) (cm/Sec)
co-primary endpoint
Time frame: Baseline, Month 12
Change in Urinary 8-iso-prostaglandin F2α (8-isoprostane)
Urine marker of oxidative stress. Values are normalized to urinary creatinine.
Time frame: Baseline, Month 12
Change in C-reactive Protein
Circulating marker of inflammation
Time frame: Baseline, Month 12
Change in Interleukin-6
Circulating marker of inflammation
Time frame: Baseline, Month 12
Percent Change in Oxidative Stress-associated Suppression of Endothelium-dependent Dilation (EDD)
The influence of oxidative stress on FMD-BA will be determined by infusing a supraphysiological dose of ascorbic acid known to scavenge superoxide or isovolumic saline. The outcome measure describes the value of the percent change with ascorbic acid compared to saline observed at baseline and the value of the percent change with ascorbic acid compared to saline at the month 12 timepoint.
Time frame: Baseline, Month 12
Change in Oxidative Stress-Associated Suppression of Large Elastic Artery Stiffness
The influence of oxidative stress on aPWV will be determined by infusing a supraphysiological dose of ascorbic acid known to scavenge superoxide or isovolumic saline.
Time frame: Baseline, Month 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.